SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,952,417 | -17.1% | 134,464 | +19.6% | 0.23% | -7.7% |
| Q2 2023 | $2,353,872 | +17.1% | 112,464 | +18.1% | 0.25% | +2.9% |
| Q1 2023 | $2,010,814 | +23.1% | 95,209 | +48.3% | 0.24% | 0.0% |
| Q4 2022 | $1,634,068 | +7.0% | 64,207 | +1.0% | 0.24% | +16.0% |
| Q3 2022 | $1,527,000 | +31.1% | 63,551 | +5.0% | 0.21% | +35.5% |
| Q2 2022 | $1,165,000 | +5.5% | 60,551 | -4.7% | 0.15% | +15.2% |
| Q1 2022 | $1,104,000 | +348.8% | 63,516 | +81.3% | 0.13% | +407.7% |
| Q2 2018 | $246,000 | -52.9% | 35,027 | -4.6% | 0.03% | -60.0% |
| Q1 2018 | $522,000 | -28.3% | 36,714 | -55.8% | 0.06% | -13.3% |
| Q4 2017 | $728,000 | +16.3% | 83,139 | +55.3% | 0.08% | -13.8% |
| Q3 2017 | $626,000 | -19.0% | 53,532 | -3.3% | 0.09% | -16.3% |
| Q2 2017 | $773,000 | – | 55,368 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |